Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Functional disability and quality of life (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher quality of life: number of participants with clinically significant… compared with placebo (high certainty).
1 finding from 1 review
Severity, reduction or cessation in nausea/vomiting 2. Number of episodes of emesis 3. Quality of life outcomes · Pregnant women with hyperemesis gravidarum
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0… compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life measured via Sickness Impact Profile, PGWB Positive well‐being, and EuroQoL Current Health Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review